TY - JOUR
T1 - Development of Indicators to Assess Quality of Care for Prostate Cancer
AU - Nag, Nupur
AU - Millar, Jeremy
AU - Davis, Ian D.
AU - Costello, Shaun
AU - Duthie, James B.
AU - Mark, Stephen
AU - Delprado, Warick
AU - Smith, David
AU - Pryor, David
AU - Galvin, David
AU - Sullivan, Frank
AU - Murphy, Áine C.
AU - Roder, David
AU - Elsaleh, Hany
AU - Currow, David
AU - White, Craig
AU - Skala, Marketa
AU - Moretti, Kim L.
AU - Walker, Tony
AU - De Ieso, Paolo
AU - Brooks, Andrew
AU - Heathcote, Peter
AU - Frydenberg, Mark
AU - Thavaseelan, Jeffery
AU - Evans, Sue M.
PY - 2018/1
Y1 - 2018/1
N2 - Background: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care. Objective: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa). Design, setting, and participants: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results. Outcome measurements and statistical analysis: Panellists were asked to rate each proposed indicator on a Likert scale of 1–9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR-ANZ). Results and limitations: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ. Conclusions: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes. Patient summary: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care. This paper identifies 12 important measurable quality indicators in prostate cancer care. These measures provide a global standard for registries to benchmark quality of care of men with localised prostate cancer.
AB - Background: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care. Objective: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa). Design, setting, and participants: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results. Outcome measurements and statistical analysis: Panellists were asked to rate each proposed indicator on a Likert scale of 1–9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR-ANZ). Results and limitations: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ. Conclusions: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes. Patient summary: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care. This paper identifies 12 important measurable quality indicators in prostate cancer care. These measures provide a global standard for registries to benchmark quality of care of men with localised prostate cancer.
KW - Clinical registries
KW - Population health
KW - Prostate cancer
KW - Quality indicators
KW - Quality measures
UR - http://www.scopus.com/inward/record.url?scp=85048625384&partnerID=8YFLogxK
U2 - 10.1016/j.euf.2016.01.016
DO - 10.1016/j.euf.2016.01.016
M3 - Article
C2 - 28753751
AN - SCOPUS:85048625384
VL - 4
SP - 57
EP - 63
JO - European Urology Focus
JF - European Urology Focus
SN - 2405-4569
IS - 1
ER -